{"entity":{"id":"nct07383922","kind":"trial","name":"A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer","aka":[],"tldr":"A phase 3 trial of nab-paclitaxel and gemcitabine in pancreatic cancer, run by FutureGen Biopharmaceutical (Beijing) Co., Ltd, not yet recruiting.","summary":"A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer is a phase 3, randomised interventional study registered as NCT07383922 by FutureGen Biopharmaceutical (Beijing) Co., Ltd, with a registry enrolment figure of 524 participants, started 2026-02-28 and due to reach its primary completion in 2030-06-30. Interventions recorded: FG-M108; nab paclitaxel; Gemcitabine (GEM); Placebo for FG-M108. Conditions listed: Pancreatic Cancer. Primary outcome: Overall Survival (OS). Pancreatic eligibility wording from the registry: \"* Histologically or cytologically confirmed unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma, without prior systemic therapy; or for subjects who have received prior neoadjuvant/adjuvant chemotherapy, the time from the last treatment to disease recurrence is \\>6 months;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07383922","url":"https://clinicaltrials.gov/study/NCT07383922"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["nab-paclitaxel","gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07383922","phase":"3","setting":"A Randomized, Double-blind, Placebo-controlled Phase 3 Study Comparing the Efficacy and Safety of FG-M108 Versus Placebo Combined With Standard Chemotherapy in First-line Treatment of Patients With Claudin18.2-Positive Advanced Pancreatic Cancer","sponsor":"FutureGen Biopharmaceutical (Beijing) Co., Ltd","enrolled":524,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07383922/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}